Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Boehringer Ingelheim
McKinsey
Moodys
Baxter

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR APREMILAST

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Apremilast

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00456092 Phase II Study With CC-10004 in Psoriatic Arthritis Completed Celgene Corporation Phase 2 2009-01-01 This study is to look at the preliminary efficacy and safety of CC-10004 vs placebo in patients with active psoriatic arthritis. The pharmacokinetics of the compound in patients will also be explored, and biopsies will be taken of the skin and the knee synovium to look at the activity of the drug in the relevant tissues.
NCT00521339 Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis Completed Celgene Corporation Phase 2 2007-08-01 The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis.
NCT00604682 Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis Completed Celgene Corporation Phase 2 2005-01-01 Open label study for patients with severe plaque type psoriasis. This study is looking to evaluate the pharmacodynamic effect of CC10004 when taken for 29 days in reducing the epidermal thickness in subjects with severe placque type psoriasis.
NCT00606450 Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis Completed Celgene Corporation Phase 2 2006-04-01 There is an unmet medical need for safe, effective oral therapy for moderate-to-severe psoriasis. CC-10004 will be evaluated in a controlled setting of a clinical study. The information obtained from the study will aid in the design of future clinical trials and to establish the safety and efficacy of CC-10004.
NCT00708916 Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients Completed Celgene Corporation Phase 1/Phase 2 2008-06-01 The purpose of this study is to determine the clinical and immunological effects of the phosphodiesterase type 4 inhibitor, CC-10004, on skin inflammation associated with cutaneous lupus erythematosus.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Apremilast

Condition Name

Condition Name for Apremilast
Intervention Trials
Psoriasis 17
Psoriatic Arthritis 10
Plaque Psoriasis 8
Healthy Volunteers 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Apremilast
Intervention Trials
Psoriasis 34
Arthritis 14
Arthritis, Psoriatic 13
Dermatitis 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Apremilast

Trials by Country

Trials by Country for Apremilast
Location Trials
United States 348
Canada 85
Japan 35
Australia 26
Germany 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Apremilast
Location Trials
Florida 23
California 23
New York 20
Texas 19
Illinois 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Apremilast

Clinical Trial Phase

Clinical Trial Phase for Apremilast
Clinical Trial Phase Trials
Phase 4 18
Phase 3 19
Phase 2 31
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Apremilast
Clinical Trial Phase Trials
Completed 23
Recruiting 22
Not yet recruiting 20
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Apremilast

Sponsor Name

Sponsor Name for Apremilast
Sponsor Trials
Celgene Corporation 47
Celgene 18
Icahn School of Medicine at Mount Sinai 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Apremilast
Sponsor Trials
Industry 71
Other 43
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Colorcon
Harvard Business School
Johnson and Johnson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.